You might be seeing the scale move in the right direction, but you may also notice new sensations in your body that you didnt anticipate
Habeners lab, has also contributed significantly to the discovery and application of GLP-based drugs
The severity and duration of these symptoms vary considerably between individuals and between different GLP-1 medications
We leverage manufacturer programs for savings and copay assistance, and for those without insurance, we discuss all financial solutions to make treatments accessible
The timing depends on the FDA's rigorous review process of the clinical trial data on retatrutide once it is submitted, however, it is unlikely to be approved and available until at least late 2026 and possibly into 2027 or 2028
Our tester has been on board for 12 months to vet Nooms promise of lasting weight loss and productive paradigm shifts to reframe your relationship with food